Knome Selected as a Genome Interpretation Partner for Illumina, Inc. (ILMN) Genome Network  
4/3/2012 10:15:52 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Knome Inc., the human genome interpretation company, announced today that it has been selected by Illumina, Inc., (NASDAQ: ILMN) as a partner in the Illumina Genome Network (IGN). As part of the agreement, IGN customers will have access to preferential pricing for Knomeā€™s genome interpretation tools and services. The agreement also calls for the companies to further integrate their data pipelines in order to provide end users with accelerated turnaround times.